Related Experiment Video
Updated: May 6, 2026
08:06
Murine Model for Parkinson's Disease: from 6-OH Dopamine Lesion to Behavioral Test
Published on: January 15, 2010
31.1K
[Apomorphine in advanced Parkinson disease].
1prof. dr hab. Andrzej Bogucki, Klinika Chorób Układu Pozapiramidowego, Uniwersytet Medyczny w Łodzi, III Szpital Miejski im. dr. Karola Jonschera, ul. Milionowa 14, 93-113 £ódŸ, Polska,
Neurologia I Neurochirurgia Polska
|October 30, 2013
Summary
Apomorphine, a potent dopamine agonist, offers rapid relief for Parkinson disease (PD) off periods via subcutaneous injections or continuous infusions. It provides continuous dopaminergic stimulation, improving motor fluctuations in advanced PD.
Area of Science:
- Neurology
- Pharmacology
Background:
- Apomorphine is a potent dopamine receptor agonist with symptomatic efficacy comparable to levodopa for Parkinson disease (PD).
- Subcutaneous administration of apomorphine ensures rapid absorption, with peak plasma concentrations and clinical effects achieved quickly.
Purpose of the Study:
- To evaluate the effectiveness of apomorphine as rescue therapy for unpredictable off periods in advanced Parkinson disease.
- To assess the role of continuous apomorphine infusion in providing sustained dopaminergic stimulation and managing motor complications.
Main Methods:
- Utilized intermittent subcutaneous injections and continuous subcutaneous infusions of apomorphine.
- Compared apomorphine infusion therapy with intraduodenal levodopa and deep brain stimulation (DBS) for advanced PD.
Main Results:
- Apomorphine injections are effective for managing unpredictable off periods in advanced PD.
- Continuous apomorphine infusion provides consistent benefits for 'off' periods, though improvements in dyskinesia are less pronounced.
- Apomorphine infusions are a viable option for advanced PD patients with motor complications who are ineligible for DBS due to cognitive issues or contraindications.
Conclusions:
- Apomorphine is a valuable therapeutic option for advanced Parkinson disease, particularly for managing motor fluctuations.
- Continuous apomorphine infusion offers sustained symptom control and is a suitable alternative to DBS in specific patient populations.
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
01:15Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
01:24Parkinson Disease l: Introduction
28
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
28
01:24Parkinson Disease ll: Pathophysiology
34
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
34
01:11Alterations in Muscle Tone lll
37
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
37
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
1.2K
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
1.2K